Literature DB >> 29326147

Elephant in the Room: Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.

Cynthia A Jackevicius1.   

Abstract

Entities:  

Keywords:  Editorials; cost-benefit analysis; drug industry; government; health insurance exchanges

Mesh:

Substances:

Year:  2018        PMID: 29326147     DOI: 10.1161/CIRCOUTCOMES.117.004425

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


× No keyword cloud information.
  1 in total

1.  Just Price for PCSK9 Inhibitors: No less, No More.

Authors:  Khurram Nasir
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.